1. Home
  2. LDI vs SGHT Comparison

LDI vs SGHT Comparison

Compare LDI & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo loanDepot Inc.

LDI

loanDepot Inc.

HOLD

Current Price

$0.60

Market Cap

542.4M

Sector

Finance

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$9.53

Market Cap

489.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDI
SGHT
Founded
2010
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
542.4M
489.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
LDI
SGHT
Price
$0.60
$9.53
Analyst Decision
Sell
Buy
Analyst Count
4
8
Target Price
$1.13
★ $10.17
AVG Volume (30 Days)
★ 3.0M
305.7K
Earning Date
11-09-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 28.16
EPS
★ N/A
N/A
Revenue
N/A
★ $77,363,000.00
Revenue This Year
$1.77
$16.75
Revenue Next Year
$8.43
$11.78
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.48
$3.38
52 Week High
$3.24
$9.71

Technical Indicators

Market Signals
Indicator
LDI
SGHT
Relative Strength Index (RSI) 47.55 64.12
Support Level $0.57 $7.88
Resistance Level $1.19 $9.71
Average True Range (ATR) 0.06 0.45
MACD 0.02 0.06
Stochastic Oscillator 62.78 93.51

Price Performance

Historical Comparison
LDI
SGHT

About LDI loanDepot Inc.

loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: